IPSC (Century Therapeutics) Total Assets: $326.6 Mil (As of Mar. 2026)


IPSC Century Therapeutics Inc IPSC
46 GF Score
Price $2.31
GF Value $38.91
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Century Therapeutics Total Assets?

Century Therapeutics IPSC -0.22% 46 Total Assets is $326.6 Mil as of Mar. 2026. GuruFocus rates IPSC with a GF Score™ of 46/100 and a GF Value™ of $38.91 (Possible Value Trap). The stock has 3 warning signs investors should review.

Century Therapeutics's Total Assets for the quarter that ended in Mar. 2026 was $326.6 Mil.

During the past 12 months, Century Therapeutics's average Total Assets Growth Rate was 27.40% per year. During the past 3 years, the average Total Assets Growth Rate was -14.60% per year. During the past 5 years, the average Total Assets Growth Rate was 16.90% per year.

During the past 7 years, Century Therapeutics's highest 3-Year average Total Assets Growth Rate was 163.40%. The lowest was -14.60%. And the median was 36.85%.

Total Assets is connected with ROA %. Century Therapeutics's annualized ROA % for the quarter that ended in Mar. 2026 was -31.47%. Total Assets is also linked to Revenue through Asset Turnover. Century Therapeutics's Asset Turnover for the quarter that ended in Mar. 2026 was 0.00.

Century Therapeutics  (NAS:IPSC) Total Assets Explanation

Total Assets is connected with ROA %.

Century Therapeutics's annualized ROA % for the quarter that ended in Mar. 2026 is

ROA %=Net Income (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=-86.58/( (223.704+326.553)/ 2 )
=-86.58/275.1285
=-31.47 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Century Therapeutics's Asset Turnover for the quarter that ended in Mar. 2026 is

Asset Turnover
=Revenue (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=0/( (223.704+326.553)/ 2 )
=0/275.1285
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Century Therapeutics Total Assets Related Terms

Century Therapeutics Total Assets Historical Data

* Premium members only.

The historical data trend for Century Therapeutics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Century Therapeutics Total Assets Chart

Century Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Assets
Get a 7-Day Free Trial 437.38 486.54 360.69 353.22 223.70

Century Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 315.61 284.69 244.72 223.70 326.55
IPSC
46GF Score
Century Therapeutics Inc IPSC
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Century Therapeutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Century Therapeutics's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (A: Dec. 2025 )+Total Liabilities (A: Dec. 2025 )
=158.936+64.768
=223.7

Century Therapeutics's Total Assets for the quarter that ended in Mar. 2026 is calculated as

Total Assets=Total Equity (Q: Mar. 2026 )+Total Liabilities (Q: Mar. 2026 )
=264.744+61.809
=326.6

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of $326.6 Mil mean?
Century Therapeutics (IPSC) has a Total Assets of $326.6 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Century Therapeutics and its competitors.
Is Century Therapeutics' Total Assets too high?
Century Therapeutics' current Total Assets is $326.6 Mil. Overall, Century Therapeutics has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Century Therapeutics' Total Assets compare to PBYI and BNTC?
Century Therapeutics' Total Assets of $326.6 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Century Therapeutics and its competitors. Century Therapeutics's current Total Assets is $326.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Century Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Century Therapeutics (IPSC) is currently considered Possible Value Trap. The stock's GF Value™ is $38.91, compared to a current price of $2.31 — trading 94.1% below its estimated fair value. The current Total Assets is $326.6 Mil. Century Therapeutics' overall GF Score™ is 46/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Century Therapeutics (IPSC), the current Total Assets is $326.6 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Century Therapeutics (IPSC) Overvalued in 2026?

Based on GuruFocus' analysis, Century Therapeutics stock appears to be undervalued. The current stock price of $2.31 is trading 94.1% below its estimated GF Value™ of $38.91. GuruFocus considers Century Therapeutics to be Possible Value Trap.

Key valuation signals for IPSC:

  • Total Assets: $326.6 Mil
  • GF Value™: $38.91 vs. price of $2.31 (94.1% below fair value)
  • GF Score™: 46/100 with 3 warning signs

No single metric tells the full story. See the IPSC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Century Therapeutics Business Description

Address 25 N 38th Street, 11th Floor, Philadelphia, PA, USA, 19104
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.
46GF Score

Get the complete analysis for IPSC

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.31
Price
$38.91
GF Value